Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sacrificing expertise

Eliminating financial conflict-of-interest waivers would lower the expertise of FDA advisory committee members, according to a report commissioned by the agency. The study of 124 standing advisory committee members who participated in 16 advisory committee meetings from Dec. 14, 2005 to Oct. 4,

Read the full 435 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers